Home
Øivind F. Grytten Torkildsen's picture

Øivind F. Grytten Torkildsen

Professor
  • E-mailOivind.Torkildsen@uib.no
  • Visitor Address
    Nevrologisk avdeling, Haukeland Universitetssykehus
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2020. Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. Journal of Neuroimmunology.
  • 2019. The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS). Multiple Sclerosis and Related Disorders. 1-6.
  • 2019. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Multiple Sclerosis. 1-9.
  • 2019. Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Multiple Sclerosis. 1-12.
  • 2019. Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. Journal of Neuroimmunology.
  • 2018. α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Multiple Sclerosis. 987-993.
  • 2018. Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. Journal of Neuroimmunology. 73-77.
  • 2018. International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis. 1-10.
  • 2018. Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. Journal of Neuroimmunology. 61-65.
  • 2017. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and neuroinflammation. 1-8.
  • 2017. Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. Multiple Sclerosis. 213-219.
  • 2017. In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. Journal of Proteome Research. 179-194.
  • 2017. Glitazone use associated with reduced risk of Parkinson's disease. Movement Disorders. 1594-1599.
  • 2017. Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. Multiple Sclerosis. 395-402.
  • 2017. An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy. 1627-1635.
  • 2017. 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochemistry International. 262-277.
  • 2016. WT1 and interferon-β–vitamin D association in MS: a longitudinal study. Acta Neurologica Scandinavica. 309-312.
  • 2016. Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. European Journal of Neurology. 1064-1070.
  • 2016. The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. Journal of Proteomics & Bioinformatics.
  • 2016. No association of tobacco use and disease activity in multiple sclerosis. Neurology: Neuroimmunology and neuroinflammation. 5 pages.
  • 2016. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
  • 2016. Familieplanlegging, graviditet og amming ved multippel sklerose. Tidsskrift for Den norske legeforening. 1726-1729.
  • 2016. Disease-modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology. 18-27.
  • 2016. Detection of varicella-zoster virus DNA during medullary and brainstem relapses in multiple sclerosis. BMJ Case Reports.
  • 2015. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology. 2713-2721.
  • 2015. Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 21-28.
  • 2015. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
  • 2015. Miljøets betydning ved multippel sklerose. Tidsskrift for Den norske legeforening. 856-860.
  • 2015. Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International. 28-40.
  • 2015. Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology. 180-186.
  • 2015. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicantre study. Multiple Sclerosis. 1013-1024.
  • 2015. Cerebrospinal fluid proteomics in multiple sclerosis. Biochimica et Biophysica Acta - Proteins and Proteomics. 746-756.
  • 2015. Body mass index influence interferon-beta treatment response in multiple sclerosis. Journal of Neuroimmunology. 92-97.
  • 2014. Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of clinical and translational neurology. 141-144.
  • 2014. Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology. 60-65.
  • 2014. Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 1178-1186.
  • 2014. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis. 1833-1840.
  • 2013. Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. Journal of Neurology. 1481-1488.
  • 2013. Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Multiple Sclerosis. 451-457.
  • 2013. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nature Medicine. 595-602.
  • 2013. No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Annals of Neurology. 430-432.
  • 2013. Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. Multiple Sclerosis. 1028-1034.
  • 2013. Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLOS ONE. 9 pages.
  • 2013. Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurologica Scandinavica. 16-23.
  • 2013. Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLOS ONE.
  • 2013. Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. PLOS ONE. 5 pages.
  • 2012. ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. Archives of Neurology. 1044-1051.
  • 2012. Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurologica Scandinavica. 63-69.
  • 2012. Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology. 267-273.
  • 2012. The cuprizone model: regional heterogeneity of pathology. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 648-657.
  • 2012. Month of birth as a risk factor for multiple sclerosis: an update. Acta Neurologica Scandinavica. 58-62.
  • 2012. Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Acta Neurologica Scandinavica, Supplementum. 84-89.
  • 2012. A need for national registries and international collaborative research in multiple sclerosis. Acta Neurologica Scandinavica. 1-3.
  • 2011. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLOS ONE. 8 pages.
  • 2010. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
  • 2009. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Experimental Neurology. 160-166.
  • 2009. A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. Clinical Nutrition. 83-87.
  • 2008. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Archives of Neurology. 809-811.
  • 2008. The cuprizone model for demyelination. Acta Neurologica Scandinavica. 72-76.
  • 2007. Immunomodulatory treatment of multiple sclerosis in Norway. Acta Neurologica Scandinavica. 46-50.
  • 2006. Fc gamma R and multiple sclerosis: an overview. Acta Neurologica Scandinavica. 61-63.
  • 2005. Lars Hertervig og Carl Fredrik Hill - kreativitet og psykisk sykdom. Tidsskrift for Den norske legeforening. 3450-3453.
  • 2005. High dose methylprednisolone induces FcgammaR1 on granulocytes in MS-patients. Journal of Neuroimmunology. 138-142.
  • 2005. Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. Scandinavian Journal of Immunology. 71-74.
  • 2005. Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology. 416-421.
Academic lecture
  • 2015. Vitamin D og interferon-behandling ved multippel sklerose.
Editorial
  • 2016. Can Vitamin D reduce inflammation in relapsing-remitting multiple sclerosis? Expert Review of Neurotherapeutics. 233-235.
Reader opinion piece
  • 2010. Vitamin D-Dependent Rickets, HIA-DRB1, and the Risk of Multiple Sclerosis. Archives of Neurology. 1034-1035.
Short communication
  • 2016. Trombolytisk behandling og trombektomi ved ukjent slagdebut. Tidsskrift for Den norske legeforening. 1363-1363.
  • 2016. Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. Headache. 1035-1039.
  • 2014. Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. Neurology: Neuroimmunology and neuroinflammation.
  • 2008. Epstein-Barr virus reactivation and multiple sclerosis. European Journal of Neurology. 106-108.
Feature article
  • 2018. Mann i 20-årene med svimmelhet, dobbeltsyn og perifer facialisparese. Tidsskrift for Den norske legeforening. 7 pages.
Letter to the editor
  • 2018. Response to 'Seasonal variation of vitamin D and Epstein?Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'. European Journal of Neurology. e104-e104.
  • 2017. Re: Familieplanlegging, graviditet og amming ved multippel sklerose. Tidsskrift for Den norske legeforening. 259-259.
  • 2015. Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'. Acta Neurologica Scandinavica. 368-369.
  • 2014. Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of clinical and translational neurology. 376-377.
  • 2014. Re: Vitamin D-how much is enough, and is more better for your Health? Tidsskrift for Den norske legeforening. 1024-1025.
Doctoral dissertation
  • 2010. Environmental risk factors for multiple sclerosis : results from animal and human studies on diet, vitamin D and Epstein-Barr virus.
Academic chapter/article/Conference paper
  • 2014. Multippel Sklerose. 10 pages.
Abstract
  • 2017. alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. Multiple Sclerosis. 712-712.
  • 2017. Cancer risk in multiple sclerosis. Multiple Sclerosis. 486-487.
  • 2013. Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. Multiple Sclerosis. 400-400.
  • 2009. Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. Multiple Sclerosis. S5-S5.
  • 2009. Histopathological characterisation of the cuprizone model for demyelination. Multiple Sclerosis. S177-S177.
  • 2008. Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. Multiple Sclerosis. S90-S91.
  • 2007. Increasing prevalence of multiple sclerosis in the elderly in western Norway. Multiple Sclerosis. S96-S96.
Academic literature review
  • 2020. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. 15 pages.
  • 2019. Neurofilament light chain as a biomarker in multiple sclerosis. 1-6.
  • 2019. B cell depletion in the treatment of multiple sclerosis. 261-271.
  • 2019. An Update on Vitamin D and Disease Activity in Multiple Sclerosis. 1187-1199.
  • 2015. Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. 29-36.
  • 2015. The Norwegian Multiple Sclerosis Registry and Biobank. 24-28.
  • 2013. Neuromyelitis optica. 2057-2061.
  • 2012. Polyunsaturated fatty acids in multiple sclerosis therapy. 70-75.
  • 2012. Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis—Association and Causation. 3701-3730.
Article in business/trade/industry journal
  • 2018. Severe multiple sclerosis reactivation after gonadotropin treatment. Multiple Sclerosis and Related Disorders. 38-40.

More information in national current research information system (CRIStin)